Evidence map›Paper›PMID 26038524›Full record

Trial reportCirculation. Cardiovascular quality and outcomes2015

Early Medication Nonadherence After Acute Myocardial Infarction: Insights into Actionable Opportunities From the TReatment with ADP receptor iNhibitorS: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) Study.

Robin Mathews, Eric D Peterson, Emily Honeycutt, Chee Tang Chin, Mark B Effron, Marjorie Zettler, Gregg C Fonarow, Timothy D Henry, Tracy Y Wang

2 registry-linked trialsOpen access · bronzeAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Circulation. Cardiovascular quality and outcomes, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 32 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 1 pooled it
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01088503 completednot on this map

The TRANSLATE-ACS Study: Treatment With ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome

TypeobservationalSponsorEli Lilly and CompanyRan2010 to 2014Enrolled12,227ConditionsAcute Coronary SyndromeArmsADP receptor inhibitors
NCT05622292 naunknown statusnot on this mapstarted 2022, after this paper: background citation

The Effectivity of the Mobile App "HARKIT I-Care" in Secondary Prevention in Post Acute Coronary Syndrome Patients in National Cardiovascular Center Harapan Kita Hospital

TypeinterventionalSponsorNational Cardiovascular Center Harapan Kita Hospital IndonesiaRan2022 to 2023Enrolled60ConditionsAcute Coronary SyndromeArmsHARKIT I-Care Application
3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 1 synthesis or guideline pooled it, 71 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Observational
  18. Observational
  19. Prasugrel use and clinical outcomes by age among patients undergoing PCI for acute coronary syndrome: from the PROMETHEUS study.Clinical research in cardiology : official journal of the German Cardiac Society · 2020
    Observational
  20. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Robin MathewsFrom the Duke Clinical Research Institute, Durham, NC (R.M., E.D.P., E.H., T.Y.W.); National Health Centre Singapore, Singapore, Singapore (C.T.C.); Lilly, USA, LLC, Indianapolis (M.B.E., M.Z.); Ahmanson-UCLA Cardiomyopathy Center, University of California Los Angeles (G.C.F.); and Minneapolis Heart Institute Foundation at Abbott Northwestern Hospital (T.D.H.). robin.mathews@duke.edu.
Eric D PetersonFrom the Duke Clinical Research Institute, Durham, NC (R.M., E.D.P., E.H., T.Y.W.); National Health Centre Singapore, Singapore, Singapore (C.T.C.); Lilly, USA, LLC, Indianapolis (M.B.E., M.Z.); Ahmanson-UCLA Cardiomyopathy Center, University of California Los Angeles (G.C.F.); and Minneapolis Heart Institute Foundation at Abbott Northwestern Hospital (T.D.H.).
Emily HoneycuttFrom the Duke Clinical Research Institute, Durham, NC (R.M., E.D.P., E.H., T.Y.W.); National Health Centre Singapore, Singapore, Singapore (C.T.C.); Lilly, USA, LLC, Indianapolis (M.B.E., M.Z.); Ahmanson-UCLA Cardiomyopathy Center, University of California Los Angeles (G.C.F.); and Minneapolis Heart Institute Foundation at Abbott Northwestern Hospital (T.D.H.).
Chee Tang ChinFrom the Duke Clinical Research Institute, Durham, NC (R.M., E.D.P., E.H., T.Y.W.); National Health Centre Singapore, Singapore, Singapore (C.T.C.); Lilly, USA, LLC, Indianapolis (M.B.E., M.Z.); Ahmanson-UCLA Cardiomyopathy Center, University of California Los Angeles (G.C.F.); and Minneapolis Heart Institute Foundation at Abbott Northwestern Hospital (T.D.H.).
Mark B EffronFrom the Duke Clinical Research Institute, Durham, NC (R.M., E.D.P., E.H., T.Y.W.); National Health Centre Singapore, Singapore, Singapore (C.T.C.); Lilly, USA, LLC, Indianapolis (M.B.E., M.Z.); Ahmanson-UCLA Cardiomyopathy Center, University of California Los Angeles (G.C.F.); and Minneapolis Heart Institute Foundation at Abbott Northwestern Hospital (T.D.H.).
Marjorie ZettlerFrom the Duke Clinical Research Institute, Durham, NC (R.M., E.D.P., E.H., T.Y.W.); National Health Centre Singapore, Singapore, Singapore (C.T.C.); Lilly, USA, LLC, Indianapolis (M.B.E., M.Z.); Ahmanson-UCLA Cardiomyopathy Center, University of California Los Angeles (G.C.F.); and Minneapolis Heart Institute Foundation at Abbott Northwestern Hospital (T.D.H.).
Gregg C FonarowFrom the Duke Clinical Research Institute, Durham, NC (R.M., E.D.P., E.H., T.Y.W.); National Health Centre Singapore, Singapore, Singapore (C.T.C.); Lilly, USA, LLC, Indianapolis (M.B.E., M.Z.); Ahmanson-UCLA Cardiomyopathy Center, University of California Los Angeles (G.C.F.); and Minneapolis Heart Institute Foundation at Abbott Northwestern Hospital (T.D.H.).
Timothy D HenryFrom the Duke Clinical Research Institute, Durham, NC (R.M., E.D.P., E.H., T.Y.W.); National Health Centre Singapore, Singapore, Singapore (C.T.C.); Lilly, USA, LLC, Indianapolis (M.B.E., M.Z.); Ahmanson-UCLA Cardiomyopathy Center, University of California Los Angeles (G.C.F.); and Minneapolis Heart Institute Foundation at Abbott Northwestern Hospital (T.D.H.).
Tracy Y WangFrom the Duke Clinical Research Institute, Durham, NC (R.M., E.D.P., E.H., T.Y.W.); National Health Centre Singapore, Singapore, Singapore (C.T.C.); Lilly, USA, LLC, Indianapolis (M.B.E., M.Z.); Ahmanson-UCLA Cardiomyopathy Center, University of California Los Angeles (G.C.F.); and Minneapolis Heart Institute Foundation at Abbott Northwestern Hospital (T.D.H.).
University of California, Los Angeles · USEli Lilly (United States) · US

Funding

Inter-disciplinary Program for Training and Mentoring in CER Methods and PracticeKM1CA156687 · NCI · DUKE UNIVERSITY · PI ABERNETHY, AMY P., DELONG, ELIZABETH R. · 2010 to 2010
$2.4M
NCI NIH HHS KM1 CA156687NCI NIH HHS KM1CA156687
6 · The paper itself

Abstract

backgroundNonadherence to prescribed evidence-based medications after acute myocardial infarction (MI) can contribute to worse outcomes and higher costs. We sought to better understand the modifiable factors contributing to early nonadherence of evidence-based medications after acute MI. METHODS AND

resultsWe assessed 7425 acute MI patients treated with percutaneous coronary intervention at 216 US hospitals participating in TReatment with ADP receptor iNhibitorS: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) between April 2010 and May 2012. Using the validated Morisky instrument to assess cardiovascular medication adherence at 6 weeks post MI, we stratified patients into self-reported high (score, 8), moderate (score, 6-7), and low (score, <6) adherence groups. Moderate and low adherence was reported in 25% and 4% of patients, respectively. One third of low adherence patients described missing doses of antiplatelet therapy at least twice a week after percutaneous coronary intervention. Signs of depression and patient-reported financial hardship because of medication expenses were independently associated with a higher likelihood of medication nonadherence. Patients were more likely to be adherent at 6 weeks if they had follow-up appointments made before discharge and had a provider explain potential side effects of their medications. Lower medication adherence may be associated with a higher risk of 3-month death/readmission (adjusted hazard ratio, 1.35; 95% confidence interval, 0.98-1.87) although this did not reach statistical significance.

conclusionsEven early after MI, a substantial proportion of patients report suboptimal adherence to prescribed medications. Tailored patient education and pre discharge planning may represent actionable opportunities to optimize patient adherence and clinical outcomes. CLINICAL

trial registrationURL: http://www.clinicaltrials.gov. Unique identifier: NCT01088503.

Indexed as

Medication AdherenceAcute Coronary SyndromeAgedElectrocardiographyFemaleFollow-Up StudiesHumansMaleMiddle AgedMyocardial InfarctionPatient DischargePercutaneous Coronary InterventionPlatelet Aggregation InhibitorsProspective StudiesPurinergic P2Y Receptor AntagonistsTime FactorsPlatelet Aggregation InhibitorsPurinergic P2Y Receptor Antagonistsacute myocardial infarctionmedication nonadherencepercutaneous coronary intervention

Identifiers

PMID26038524
PMCPMC4512913
OpenAlexW2548840405

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.